Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 10
Submit an article Journal homepage
277
Views
5
CrossRef citations to date
0
Altmetric
Commentaries

Ibrutinib and invasive fungal infections: the known, the unknown and the known unknowns

Gemma ReynoldsDepartment of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, AustraliaCorrespondence[email protected]
,
Monica SlavinDepartment of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia;National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, AustraliaORCID Iconhttps://orcid.org/0000-0002-8443-314X
ORCID Icon &
Benjamin W. TehDepartment of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia;National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, AustraliaORCID Iconhttps://orcid.org/0000-0003-0213-5470
ORCID Icon
Pages 2292-2294 | Received 06 Jul 2020, Accepted 12 Jul 2020, Published online: 23 Jul 2020

References

  • Frei M, Aitken SL, Jain N, et al. Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib. Leuk Lymphoma. 2020;60(10):2488–2491.
  • Fleming S, Yannakou C, Haeusler GM, et al. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014. Intern Med J. 2014;44(12b):1283–1297.
  • Varughese T, Taur Y, Cohen N, et al. Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer. Clin Infect Dis. 2018;67(5):687–692.
  • Ruchlemer R, Ben-Ami R, Bar-Meir M, et al. Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-hodgkin lymphoma: an observational study. Mycoses. 2019;62(12):1140–1147.
  • Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the seifem-2004 study. Haematologica. 2006;91(8):1068–1075.
  • Ghez D, Calleja A, Protin C, French Innovative Leukemia Organization (FILO) CLL group, et al. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 2018;131(17):1955–1959.
  • Chamilos G, Lionakis MS, Kontoyiannis DP. Call for action: invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways. Clin Infect Dis. 2018;66(1):140–148.
  • Sun C, Tian X, Lee YS, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126(19):2213–2219.
  • Rogers KA, Luay M, Zhao Q, et al. Incidence and type of opportunistic infections during ibrutinib treatment at a single academic center. Blood. 2017;130:830.
  • Bechman K, Galloway JB, Winthrop KL. Small-molecule protein kinases inhibitors and the risk of fungal infections. Curr Fungal Infect Rep. 2019;13(4):229–243.
  • Madigan V, Smibert O, Chen S, et al. Cryptococcal infection in patients with haematological and solid organ malignancy in the era of targeted and immune-based therapies. Clin Microbiol Infect. 2020;26(4):519–521.
  • Martin-Garrido I, Carmona EM, Specks U, et al. Pneumocystis pneumonia in patients treated with rituximab. Chest. 2013;144(1):258–265.
  • Ahn IE, Jerussi T, Farooqui M, et al. Atypical pneumocystis jirovecii pneumonia in previously untreated patients with cll on single-agent ibrutinib. Blood. 2016;128(15):1940–1943.
  • Luppi M, Forghieri F, Potenza L. Ibrutinib is a newly recognized host factor for the definition of probable invasive pulmonary mold disease, based on off-target effects, unrelated to its b-cell immunosuppressant activity. Clin Infect Dis. 2020. DOI:10.1093/cid/ciaa323
  • Nyga R, Delette C, Mabille C, et al. Ibrutinib related cerebral aspergillosis successfully treated with isavuconazole: a case report. Leuk Lymphoma. 2020:1–3. DOI:10.1080/10428194.2020.1728749
  • Grommes C, Younes A. Ibrutinib in pcnsl: the curious cases of clinical responses and aspergillosis. Cancer Cell. 2017;31(6):731–733.
  • Goldwirt L, Beccaria K, Ple A, et al. Ibrutinib brain distribution: a preclinical study. Cancer Chemother Pharmacol. 2018;81(4):783–789.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.